DE60324270D1 - Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung - Google Patents

Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung

Info

Publication number
DE60324270D1
DE60324270D1 DE60324270T DE60324270T DE60324270D1 DE 60324270 D1 DE60324270 D1 DE 60324270D1 DE 60324270 T DE60324270 T DE 60324270T DE 60324270 T DE60324270 T DE 60324270T DE 60324270 D1 DE60324270 D1 DE 60324270D1
Authority
DE
Germany
Prior art keywords
methylated
oxynucleotides
oligode
immunostimulating
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324270T
Other languages
German (de)
English (en)
Inventor
Ying K Tam
Sean Semple
Sandra Klimuk
Ghania Chikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/290,545 external-priority patent/US20030125292A1/en
Application filed by Tekmira Pharmaceuticals Corp filed Critical Tekmira Pharmaceuticals Corp
Application granted granted Critical
Publication of DE60324270D1 publication Critical patent/DE60324270D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60324270T 2002-05-10 2003-05-12 Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung Expired - Fee Related DE60324270D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37934302P 2002-05-10 2002-05-10
US10/290,545 US20030125292A1 (en) 2001-11-07 2002-11-07 Mucoscal vaccine and methods for using the same
US46064603P 2003-04-04 2003-04-04
PCT/CA2003/000678 WO2003094963A2 (en) 2002-05-10 2003-05-12 Methylated immunostimulatory oligonucleotides and methods of using the same

Publications (1)

Publication Number Publication Date
DE60324270D1 true DE60324270D1 (de) 2008-12-04

Family

ID=29424457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324270T Expired - Fee Related DE60324270D1 (de) 2002-05-10 2003-05-12 Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung

Country Status (10)

Country Link
EP (2) EP1503793A2 (https=)
JP (2) JP2005532315A (https=)
CN (1) CN1665531A (https=)
AT (1) ATE411815T1 (https=)
AU (2) AU2003229434A1 (https=)
CA (2) CA2485400A1 (https=)
DE (1) DE60324270D1 (https=)
IL (1) IL165107A0 (https=)
MX (1) MXPA04011127A (https=)
WO (2) WO2003094963A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
JP2012507565A (ja) 2008-10-30 2012-03-29 グオ・ペイシュエン Ｄｎａのシークエンシング及び他の用途のための、膜に組み込まれたウイルスｄｎａパッケージングモータタンパク質コネクタバイオセンサ
EP2484698A4 (en) * 2009-09-28 2014-07-02 Sysmex Corp HYBRIDOMAS FOR THE PRODUCTION OF ANTIBODIES TO METHYLATED DNA AND USE THEREOF
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
CA3183951A1 (en) * 2020-07-14 2022-01-20 Birgitte Rono Apc targeting units for immunotherapy
CN116602920B (zh) * 2023-04-18 2024-03-19 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
FI107974B (fi) * 1999-07-14 2001-10-31 Nokia Networks Oy Menetelmä ja järjestelmä tilastointiin puhelinkeskusjärjestelmässä
EP1212085B1 (en) * 1999-08-27 2007-10-31 INEX Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
EP1441763A2 (en) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid

Also Published As

Publication number Publication date
CA2485400A1 (en) 2003-11-20
WO2003094828A3 (en) 2004-02-05
AU2003229434A1 (en) 2003-11-11
WO2003094963A2 (en) 2003-11-20
EP1503793A2 (en) 2005-02-09
AU2003229434A8 (en) 2003-11-11
MXPA04011127A (es) 2005-07-01
JP2005532315A (ja) 2005-10-27
ATE411815T1 (de) 2008-11-15
AU2003229433B2 (en) 2008-04-24
WO2003094828A2 (en) 2003-11-20
WO2003094963A3 (en) 2004-02-12
CN1665531A (zh) 2005-09-07
JP2005530761A (ja) 2005-10-13
EP1506010A2 (en) 2005-02-16
IL165107A0 (en) 2005-12-18
AU2003229433A1 (en) 2003-11-11
EP1506010B1 (en) 2008-10-22
CA2484266A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DE60324270D1 (de) Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung
DE60129593D1 (de) Zusammensetzungen und verfahren zur extraktion einer nukleinsäure
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
EP1630237A3 (en) Isolation of nucleic acid fragments by hybridisation to a solid support
HUP0202639A2 (en) Immunostimulatory nucleic acids
AU2001244677A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
EP1589118A3 (en) Methods and compositions for assessing CpG methylation
BG107861A (en) Isothermal amplification of nucleic acids on a solid support
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
MX2009009530A (es) Composiciones de acidos nucleicos cerrados bicatenarios.
JP2007509983A5 (https=)
WO2005065321A3 (en) Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
MY165006A (en) Method and compositions for producing fatty alcohols
DE602006017192D1 (de) Verfahren zur herstellung von oligonukleotiden
WO2003052132A3 (en) Linear and hairpin oligonucleotide analogues comprising intercalator pseudonucleotides
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
ATE326499T1 (de) Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
IL153200A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
BR0210493A (pt) Composição, e, método para remover cerume humano
NO20023276L (no) Fremgangsmåter fremstilling av betulinsyre
DE602006002497D1 (de) Silikonmemulsion, verfahren zu ihrer herstellung und kosmetischer bestandteil
ATE252589T1 (de) Aluminosiloxanverbindungen und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee